IMS Health acquires DecisionView
IMS Health of Danbury, Conn., has acquired DecisionView, a San Francisco-based software solutions company that helps life sciences organizations plan and track patient enrollment for clinical trials around the world. DecisionView offers decision support tools to improve the speed, efficiency and performance of clinical trial planning and management.
IMS will integrate its market-leading health outcomes, provider and anonymized patient data assets with DecisionView’s advanced optimization technology, predictive analytics and performance data gathered from more than 1,200 clinical studies across 90+ countries. This combination will enable clinical trial sponsors and research organizations to base site selection and patient enrollment decisions on real-world data and benchmarks.
“Today, the clinical trial planning and enrollment process is inefficient due to the lack of real-world data and analytics in trials management and decision making,” said Andrew Kress, senior vice president, IMS Healthcare Value Solutions. “Approximately 90% of clinical trials don’t finish on time, with trial enrollment cited as the leading cause of delays. Through this acquisition, we will enhance clinical trial productivity—transforming the way patient studies are planned and executed.”
DecisionView becomes part of IMS’s Healthcare Value Solutions business, which connects healthcare stakeholders through real-world evidence to demonstrate the value of medicines, enhance quality and drive improved results. IMS Healthcare Value Solutions is focused on health economics and outcomes research, government solutions, payer and provider solutions and clinical trial optimization services that include patient enrollment and protocol feasibility.
“We’re very excited to join IMS’ team,” said Linda Drumright, DecisionView president and CEO. “Our clients recognize the need for more data and analytics to guide their clinical trial enrollment and performance management activities—and they’re actively looking for innovative solutions. The combination of DecisionView and IMS is powerful and elevates our value to clients by opening up a whole new set of possibilities for clinical trial decision-making.”
DecisionView develops web-based software solutions to help life sciences organizations improve clinical trial performance. Its flagship product, StudyOptimizer, is a web-based solution that helps clinical trial organizations plan, forecast and track patient enrollment. DecisionView Enrollment Benchmarks aggregate cross-industry performance data from clinical trials that have completed enrollment, providing insight to enable more realistic planning and forecasting. DecisionView products have been used on clinical studies with over 450,000 subjects enrolled in 17 different therapeutic areas.
IMS Health provides information, services and technology for the healthcare industry, drawing on its global technology infrastructure and combination of in-depth, sophisticated analytics, on-shore and off-shore commercial services and software platforms to help clients understand the performance and value of medicines. IMS’ clients include pharmaceutical manufacturers and distributors, providers, payers, government agencies, policymakers, researchers and the financial community, in over 100 countries.